Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 5/20 | 0.53 |
| ▸ | ACACB | O00763 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.46 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29508554 | 0.81 | CASR (0.58) | CASRSMN1; SMN2CYP2D6 | |
| SCHEMBL353903 | 0.78 | ACACB (0.51) | CASRACACBSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL1908631 | 0.76 | LTA4H (0.50) | SMN1; SMN2ALDH1A1USP2LMNACYP3A4 | |
| Etolorex SCHEMBL164620 | 0.74 | SLC6A4 (0.48) | CASRALDH1A1LMNACYP3A4CYP1A2 | |
| SCHEMBL6439235 | 0.74 | CASR (0.65) | CASRALDH1A1MEN1KMT2ACYP2D6 | |
| Hydrochloric Acid SCHEMBL5512676 | 0.73 | CASR (0.64) | CASRALDH1A1MEN1KMT2ACYP2D6 | |
| SCHEMBL5521284 | 0.73 | CASR (0.64) | CASRMEN1KMT2ACYP2D6 | |
| SCHEMBL613971 | 0.73 | SLC6A2 (0.50) | SMN1; SMN2LMNAKDM4ECYP1A2CYP2D6 | |
| SCHEMBL5511560 | 0.72 | CASR (0.67) | CASRALDH1A1MEN1KMT2ACYP2D6 | |
| SCHEMBL7837295 | 0.72 | ALDH1A1 (0.66) | SMN1; SMN2ALDH1A1MEN1KMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270188-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2025-08-28 | — | — | US | disclosed |
| US-12378222-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2025-08-05 | — | — | US | disclosed |
| EP-4577550-A1 | NOVEL NLRP3 INFLAMMASOME INHIBITORS | Hangzhou Highlightll Pharmaceutical Co., Ltd. (CN) | 2025-07-02 | — | — | EP | disclosed |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| US-20250206742-A1 | NLRP3 INFLAMMASOME INHIBITORS | HANGZHOU HIGHLIGHTLL PHARMACEUTICAL CO., LTD (CN) | 2025-06-26 | — | — | US | disclosed |
| EP-4565326-A1 | NLRP3 INFLAMMASOME INHIBITORS | Novartis AG (CH) | 2025-06-11 | — | — | EP | disclosed |
| EP-2152341-B2 | ATOMIZER IN THE FORM OF AN INHALER FOR MEDICAL AEROSOL THERAPY | BOEHRINGER INGELHEIM PHARMA (DE) | 2025-04-02 | — | — | EP | disclosed |
| CN-119732956-A | NLRP3 inflammatory corpuscle inhibitor | 诺华股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-119677725-A | NLRP3 inflammatory corpuscle inhibitor | 诺华股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-113784957-B | NLRP3 inflammatory corpuscle inhibitor | 诺华股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| EP-3436446-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11426407-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220251067-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2022-08-11 | — | — | US | disclosed |
| CN-110840847-B | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | 沃泰克斯药物股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-11369760-B2 | Inhalation atomizer comprising a blocking function and a counter | ANOVENT PHARMACEUTICAL (U.S.), LLC (US) | 2022-06-28 | — | — | US | disclosed |
| EP-2954889-B1 | INHALATION COMPOSITION CONTAINING ACLIDINIUM FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | ALMIRALL SA (ES) | 2022-05-04 | — | — | EP | disclosed |
| EP-2954891-B1 | INHALATION COMPOSITION CONTAINING ACLIDINIUM FOR TREATMENT OF ASTHMA | ALMIRALL SA (ES) | 2022-05-04 | — | — | EP | disclosed |
| EP-3969441-A1 | NLRP3 INFLAMMASOME INHIBITORS | Novartis AG (CH) | 2022-03-23 | — | — | EP | disclosed |
| US-11254653-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206742-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | CASR 455/4885ACACB 2862/4885SMN1; SMN2 4611/4885 |
| US-11426407-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | CASR 249/4885ACACB 4063/4885SMN1; SMN2 4751/4885 |
| US-11254653-B2 | NLRP3 inflammasome inhibitors | NLRP3, NLRP1, NOD1 | CASR 349/4885ACACB 3927/4885SMN1; SMN2 4766/4885 |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | CASR 249/4885ACACB 4063/4885SMN1; SMN2 4751/4885 |
| US-11369760-B2 | Inhalation atomizer comprising a blocking function and a counter | ADRB2, ADRB1, ADRA2B | CASR 1894/4885ACACB 2363/4885SMN1; SMN2 1676/4885 |
| US-20220251067-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | CASR 349/4885ACACB 3927/4885SMN1; SMN2 4766/4885 |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | CASR 249/4885ACACB 4063/4885SMN1; SMN2 4751/4885 |
| US-12378222-B2 | NLRP3 inflammasome inhibitors | NLRP3, NLRP1, NOD1 | CASR 337/4885ACACB 3751/4885SMN1; SMN2 4721/4885 |
| US-20250270188-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | CASR 349/4885ACACB 3927/4885SMN1; SMN2 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.